High-Fat and Fructose Intake Induces Insulin Resistance, Dyslipidemia, and Liver Steatosis and Alters In Vivo Macrophage-to-Feces Reverse Cholesterol Transport in Hamsters

被引:35
作者
Briand, Francois [1 ]
Thieblemont, Quentin [1 ]
Muzotte, Elodie [1 ]
Sulpice, Thierry [1 ]
机构
[1] Physiogenex SAS, Prologue Biotech, Labege, France
关键词
HIGH-DENSITY-LIPOPROTEIN; METABOLIC SYNDROME; OBESITY; BILIARY; EXCRETION; SAFETY; ABCG8; MICE;
D O I
10.3945/jn.111.153197
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Reverse cholesterol transport (RCT) promotes the egress of cholesterol from peripheral tissues to the liver for biliary and fecal excretion. Although not demonstrated in vivo, RCT is thought to be impaired in patients with metabolic syndrome, in which liver steatosis prevalence is relatively high. Golden Syrian hamsters were fed a nonpurified (CON) diet and normal drinking water or a high-fat (HF) diet containing 27% fat, 0.5% cholesterol, and 0.25% deoxycholate as well as 10% fructose in drinking water for 4 wk. Compared to CON, the HF diet induced insulin resistance and dyslipidemia, with significantly higher plasma non-HDL cholesterol concentrations and cholesteryl ester transfer protein activity. The HF diet induced severe liver steatosis, with significantly higher cholesterol and TG levels compared to CON. In vivo RCT was assessed by i.p. injecting H-3-cholesterol labeled macrophages. Compared to CON, HF hamsters had significantly greater H-3-tracer recoveries in plasma, but not HDL. After 72 h, H-3-tracer recovery in HF hamsters was 318% higher in liver and 75% lower in bile (P < 0.01), indicating that the HF diet impaired hepatic cholesterol fluxes. However, macrophage-derived cholesterol fecal excretion was 45% higher in HF hamsters than in CON hamsters. This effect was not related to intestinal cholesterol absorption, which was 89% higher in HF hamsters (P < 0.05), suggesting a possible upregulation of transintestinal cholesterol excretion. Our data indicate a significant increase in macrophage-derived cholesterol fecal excretion in a hamster model of metabolic syndrome, which may not compensate for the diet-induced dyslipidemia and liver steatosis. J. Nutr. 142: 704-709, 2012.
引用
收藏
页码:704 / 709
页数:6
相关论文
共 37 条
  • [1] Abramoff M.D., 2004, Biophotonics International, V11, P36
  • [2] Nutrition transition and its relationship to the development of obesity and related chronic diseases
    Astrup, Arne
    Dyerberg, Jorn
    Selleck, Matthew
    Stender, Steen
    [J]. OBESITY REVIEWS, 2008, 9 : 48 - 52
  • [3] Liver X receptor activation promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model
    Briand, Francois
    Treguier, Morgan
    Andre, Agnes
    Grillot, Didier
    Issandou, Marc
    Ouguerram, Khadija
    Sulpice, Thierry
    [J]. JOURNAL OF LIPID RESEARCH, 2010, 51 (04) : 763 - 770
  • [4] Briand F, 2010, CURR OPIN INVEST DR, V11, P289
  • [5] Both the Peroxisome Proliferator-Activated Receptor δ Agonist, GW0742, and Ezetimibe Promote Reverse Cholesterol Transport in Mice by Reducing Intestinal Reabsorption of HDL-Derived Cholesterol
    Briand, Francois
    Naik, Snehal U.
    Fuki, Ilia
    Millar, John S.
    Macphee, Colin
    Walker, Max
    Billheimer, Jeffrey
    Rothblat, George
    Rader, Daniel J.
    [J]. CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2009, 2 (02): : 127 - 133
  • [6] Targeted depletion of hepatic ACAT2-driven cholesterol esterification reveals a non-biliary route for fecal neutral sterol loss
    Brown, J. Mark
    Bell, Thomas A., III
    Alger, Heather M.
    Sawyer, Janet K.
    Smith, Thomas L.
    Kelley, Kathryn
    Shah, Ramesh
    Wilson, Martha D.
    Davis, Matthew A.
    Lee, Richard G.
    Graham, Mark J.
    Crooke, Rosanne M.
    Rudel, Lawrence L.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (16) : 10522 - 10534
  • [7] Reverse Cholesterol Transport Revisited Contribution of Biliary Versus Intestinal Cholesterol Excretion
    Brufau, Gemma
    Groen, Albert K.
    Kuipers, Folkert
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2011, 31 (08) : 1726 - 1733
  • [8] Metabolic disturbances in non-alcoholic fatty liver disease
    Byrne, Christopher D.
    Olufadi, Rasaq
    Bruce, Kimberley D.
    Cagampang, Felino R.
    Ahmed, Mohamed H.
    [J]. CLINICAL SCIENCE, 2009, 116 (7-8) : 539 - 564
  • [9] Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease.
    Cannon, Christopher P.
    Shah, Sukrut
    Dansky, Hayes M.
    Davidson, Michael
    Brinton, Eliot A.
    Gotto, Antonio M., Jr.
    Stepanavage, Michael
    Liu, Sherry Xueyu
    Gibbons, Patrice
    Ashraf, Tanya B.
    Zafarino, Jennifer
    Mitchel, Yale
    Barter, Philip
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (25) : 2406 - 2415
  • [10] In vivo macrophage-specific RCT and antioxidant and antiinflammatory HDL activity measurements: New tools for predicting HDL atheroprotection
    Carles Escola-Gil, Joan
    Rotllan, Noemi
    Julve, Josep
    Blanco-Vaca, Francisco
    [J]. ATHEROSCLEROSIS, 2009, 206 (02) : 321 - 327